Skip to main content
SGMT logo

Sagimet Biosciences Inc.

SGMTNASDAQHealthcareBiotechnology

$9.56Today:- (-)1Y +35.74%

As of Oct 26, 2026 close

Market cap
$507.77M
P/E (TTM)
-
Forward P/E
-
Dividend yield
-
52-week range
$4.50$11.45
Volume (live)
-
Avg. volume (3M)
1.48M

Sagimet Biosciences (SGMT) Income Statement

In fiscal 2025 (fiscal year ended Dec 31, 2025), Sagimet Biosciences posted a net loss of $51.04M, compared with a net loss of $45.57M a year earlier.

Sagimet Biosciences Income Statement Analysis

Values in millions USD

Scroll to see more
Sagimet Biosciences Inc. income statement - Annual data in millions USD
BreakdownFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019
Period endingDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019
Revenue & Gross Profit
Revenue0.000.002.000.000.000.000.00
Cost of Revenue0.000.000.000.000.000.000.09
Gross Profit0.000.002.000.000.000.00-0.09
Operating Expenses
Research & Development39.0538.4419.7824.9219.348.188.39
Selling, General & Administrative17.8416.0112.966.144.383.225.68
Operating Expenses56.8954.4532.7431.0623.7211.4014.07
Operating Income-56.89-54.45-30.74-31.06-23.72-11.40-14.16
Other Income/Expense
Interest Income5.858.892.860.550.030.030.13
Interest Expense0.000.000.000.000.000.000.06
Other Income/Expense5.858.892.860.00-0.720.03-0.10
Income
Income Before Tax-51.04-45.57-27.88-30.50-24.44-11.37-14.26
Income Tax Expense0.000.000.000.000.000.000.00
Net Income-51.04-45.57-27.88-30.50-24.44-11.37-14.26
Net Income - Continuous Operations-51.04-45.57-27.88-30.50-24.44-11.37-14.26
Net Income - Discontinued Operations-------
EBITDA-56.89-54.45-30.74-31.06-24.44-11.40-14.11
EBIT-56.89-54.45-30.74-31.06-23.72-11.40-
Depreciation & Amortization0.000.000.000.130.000.000.09
Earnings Per Share
Basic EPS-2.00-1.00-3.00-1.00-1.00-1.00-1.00
Diluted EPS-2.00-1.00-3.00-1.00-1.00-1.00-1.00
Basic Shares Outstanding32.3531.3510.4622.1722.1722.1722.17
Diluted Shares Outstanding32.3531.3510.4622.1722.1722.1722.17

Source: Company financial statements from annual and quarterly filings. Data as of Jun 30, 2026. Data sources and methodology

Frequently Asked Questions About Sagimet Biosciences Financial Statements

Is Sagimet Biosciences profitable?

No. Sagimet Biosciences reported a net loss of $51.04M in fiscal 2025. In fiscal 2024 it lost $45.57M.

What is net profit margin?

Net profit margin is net income divided by revenue. It shows how much of each dollar of sales a company keeps as profit after all costs, interest and taxes. Full definition